Quarterly ResultMay 7, 2026, 04:24 PM
Ginkgo Bioworks Completes Biosecurity Divestiture; Q1 Revenue $19.5M
AI Summary
Ginkgo Bioworks completed the divestiture of its Biosecurity business on April 3, 2026, receiving a minority equity interest in the purchaser. For Q1 2026, the company reported a net loss of $82.6 million, an improvement from $91.0 million in Q1 2025. Revenue from continuing operations decreased significantly to $19.5 million from $38.2 million year-over-year. The company also continued its restructuring plan, which substantially concluded workforce reductions by December 31, 2025, and is now focused on facility consolidation.
Key Highlights
- Completed Biosecurity business divestiture on April 3, 2026, receiving ~20% equity in Purchaser.
- Q1 2026 net loss was $82.6 million, down from $91.0 million in Q1 2025.
- Revenue from continuing operations decreased to $19.5 million from $38.2 million YoY.
- Basic net loss per share improved to $(1.39) from $(1.68) in Q1 2025.
- Research and development expenses decreased to $49.9 million from $70.9 million.
- Net cash used in operating activities was $(46.7) million, compared to $(51.5) million.
- Restructuring charges were $0 in Q1 2026, down from $4.5 million in Q1 2025.
- Cash and cash equivalents stood at $143.9 million as of March 31, 2026.